Schmalzbauer, Belinda S. (University of Veterinary Medicine Vienna) Belinda S. Schmalzbauer Kollmann, Karoline (University of Veterinary Medicine Vienna) Karoline Kollmann Sperl, Clio-Melina (University of Veterinary Medicine Vienna) Clio-Melina Sperl Schirripa, Alessia (University of Veterinary Medicine Vienna) Alessia Schirripa Thondanpallil, Teresemary (University of Veterinary Medicine Vienna) Teresemary Thondanpallil Heller, Gerwin (Medical University of Vienna) Gerwin Heller Sexl, Veronika (University of Veterinary Medicine Vienna) Veronika Sexl Klampfl, Thorsten (University of Veterinary Medicine Vienna) Thorsten Klampfl Fontaine, Frédéric (CeMM-Research Center for Molecular Medicine of the Austrian Academy of Sciences) Frédéric Fontaine Mueller, André C. (CeMM-Research Center for Molecular Medicine of the Austrian Academy of Sciences) André C. Mueller Zojer, Markus (University of Veterinary Medicine Vienna) Markus Zojer Nebenfuehr, Sofie (University of Veterinary Medicine Vienna) Sofie Nebenfuehr Knab, Vanessa M. (University of Veterinary Medicine Vienna) Vanessa M. Knab Mayer, Isabella M. (University of Veterinary Medicine Vienna) Isabella M. Mayer MDPI 2022 Cyclin-dependent kinase 6 (CDK6) represents a novel therapeutic target for the treatment of certain subtypes of acute myeloid leukaemia (AML). CDK4/6 kinase inhibitors have been widely studied in many cancer types and their effects may be limited by primary and secondary resistance mechanisms. CDK4/6 degraders, which eliminate kinase-dependent and kinase-independent effects, have been suggested as an alternative therapeutic option. We show that the efficacy of the CDK6-specific protein degrader BSJ-03-123 varies among AML subtypes and depends on the low expression of the INK4 proteins p16INK4A and p18INK4C. INK4 protein levels are significantly elevated in KMT2A-MLLT3+ cells compared to RUNX1-RUNX1T1+ cells, contributing to the different CDK6 degradation efficacy. We demonstrate that CDK6 complexes containing p16INK4A or p18INK4C are protected from BSJ-mediated degradation and that INK4 levels define the proliferative response to CDK6 degradation. These findings define INK4 proteins as predictive markers for CDK6 degradation-targeted therapies in AML. PDFDocument en 2023-07-26T08:05:04.576Z Cell-Cycle; Inhibition; Program 2081393 b application/pdf CC BY 4.0 International